@TumorBoardTues 1/17 #TumorBoardTuesday #BreastCancer #OncTwitter
56 yo 👩🏽 postmenopausal
🚫comorbidities
De novo MBC to 🦴
ER 95% PR 88%, HER2 1+ IHC/FISH neg
🗓️2.5yrs: Tx with letrozole/ribociclib/zoledronic acid
🩻NOW: Scans show progression in 🦴 and liver
🤨What would you do next?
56 yo 👩🏽 postmenopausal
🚫comorbidities
De novo MBC to 🦴
ER 95% PR 88%, HER2 1+ IHC/FISH neg
🗓️2.5yrs: Tx with letrozole/ribociclib/zoledronic acid
🩻NOW: Scans show progression in 🦴 and liver
🤨What would you do next?
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner 2/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 1👩🏻🏫
📌ESR1 mutation
📍Rarely present on initial dx (0.5%)
🔸Commonly acquired in ER+ HER2-neg MBC (14-54% prevalence)
👉🏽endocrine tx resistance ➡️ ligand-indep activation of ER
📚@RMJesel ncbi.nlm.nih.gov
📚sciencedirect.com
👩🏽🏫Mini tweetorial 1👩🏻🏫
📌ESR1 mutation
📍Rarely present on initial dx (0.5%)
🔸Commonly acquired in ER+ HER2-neg MBC (14-54% prevalence)
👉🏽endocrine tx resistance ➡️ ligand-indep activation of ER
📚@RMJesel ncbi.nlm.nih.gov
📚sciencedirect.com
ncbi.nlm.nih.gov/pmc/articles/P…
ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer
Most breast cancers are estrogen receptor α (ER)-positive (+) and are treated with endocrine therapi...
sciencedirect.com/science/articl…
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Estrogen receptor α (ER) ligand-binding domain (LBD) mutations are found in a substantial number of...
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel 3/17 #TumorBoardTuesday #BreastCancer
👩🏽🏫Mini tweetorial 2👩🏻🏫
📌ESR1 mutation & tx response
🧬(-) ESR1 mut ➡️ no difference in PFS/OS benefit bt AI or fulvestrant
🧬(+) ESR1 mut ➡️ dec PFS/OS with AI vs fulvestrant
📚pubmed.ncbi.nlm.nih.gov
📚@DrWGradishar aacrjournals.org
👩🏽🏫Mini tweetorial 2👩🏻🏫
📌ESR1 mutation & tx response
🧬(-) ESR1 mut ➡️ no difference in PFS/OS benefit bt AI or fulvestrant
🧬(+) ESR1 mut ➡️ dec PFS/OS with AI vs fulvestrant
📚pubmed.ncbi.nlm.nih.gov
📚@DrWGradishar aacrjournals.org
aacrjournals.org/clincancerres/…
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
AbstractPurpose:. ESR1 mutations are acquired frequently in hormone receptor–positive metastatic bre...
pubmed.ncbi.nlm.nih.gov/32546646/
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials - PubMed
Detection of ESR1 mutations in baseline ctDNA is associated with inferior PFS and OS in patients tre...
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @lucarecco @jhxii_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @AWolff @brunovalsi @sardesai_sagar @CarmenCriscit @JavierCortesMD
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @sardesai_sagar @CarmenCriscit @JavierCortesMD 4/17 #TumorBoardTuesday #BreastCancer
👩🏽🏫Mini tweetorial 3👩🏻🏫
✨EMERALD ✨
🎲Ph III RCT elacestrant daily vs fulvestrant q28d or AI daily
📍ER+ HER2-neg MBC
👌🏽1-2 lines of endocrine tx 👉🏽 OK to have 1 prior chemo
📚@dradityabardia futuremedicine.com
@JasmineSukumar
👩🏽🏫Mini tweetorial 3👩🏻🏫
✨EMERALD ✨
🎲Ph III RCT elacestrant daily vs fulvestrant q28d or AI daily
📍ER+ HER2-neg MBC
👌🏽1-2 lines of endocrine tx 👉🏽 OK to have 1 prior chemo
📚@dradityabardia futuremedicine.com
@JasmineSukumar
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @sardesai_sagar @CarmenCriscit @JavierCortesMD 5/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 4👩🏻🏫
✨EMERALD
📍12m PFS all pts: 22.3 mo ela vs 9.4 mo SOC (HR 0.70)
📍12m PFS pts with ESR1 mut: 26.8 mo ela vs 8.2 mo SOC (HR 0.55)
👍🏽Good safety/tolerability🦺 (≥G3 AEs➡️ 7.2% ela / 3.1% SOC)
📚@dradityabardia pubmed.ncbi.nlm.nih.gov
👩🏽🏫Mini tweetorial 4👩🏻🏫
✨EMERALD
📍12m PFS all pts: 22.3 mo ela vs 9.4 mo SOC (HR 0.70)
📍12m PFS pts with ESR1 mut: 26.8 mo ela vs 8.2 mo SOC (HR 0.55)
👍🏽Good safety/tolerability🦺 (≥G3 AEs➡️ 7.2% ela / 3.1% SOC)
📚@dradityabardia pubmed.ncbi.nlm.nih.gov
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @sardesai_sagar @CarmenCriscit @JavierCortesMD 6/17 #TumorBoardTuesday @nlinmd @angela_toss #BreastCancer
Back to our case🔎
🧬NGS: ESR1 mutation positive
➡️ start elacestrant
📆 Does well for 9 months
🥱Asymptomatic except G1 fatigue
BUT
🩻Imaging shows 2 new liver lesions, including new 🦴activity
🤨 Next treatment?
Back to our case🔎
🧬NGS: ESR1 mutation positive
➡️ start elacestrant
📆 Does well for 9 months
🥱Asymptomatic except G1 fatigue
BUT
🩻Imaging shows 2 new liver lesions, including new 🦴activity
🤨 Next treatment?
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi 7/17 #TumorBoardTuesday #BreastCancer @fumikochino @stage4kelly @MammaMiaMagazin @amybeumer
👩🏽🤝👩🏻⚕️
🗣️Discuss all chemo options with patient and family‼️#SharedDecision
🤔What fits with patient goals and QOL?
💸Other costs of tx: time, financial, physical
📚@AmericanCancer
👩🏽🤝👩🏻⚕️
🗣️Discuss all chemo options with patient and family‼️#SharedDecision
🤔What fits with patient goals and QOL?
💸Other costs of tx: time, financial, physical
📚@AmericanCancer
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @MammaMiaMagazin @AmericanCancer 8/17 #TumorBoardTuesday #BCSM
👩🏽🏫Mini tweetorial 5👩🏻🏫
✨DESTINY-Breast 04✨
📌T-DXd in HER2-low (+1, +2, neg FISH) MBC
📍Ph III comparing T-Dxd vs 👨🏾⚕️ choice chemo
💉1-2 lines of prior chemo
📈Vast improvement in PFS and OS in HER2-low pop
📚#ShanuModi nejm.org
👩🏽🏫Mini tweetorial 5👩🏻🏫
✨DESTINY-Breast 04✨
📌T-DXd in HER2-low (+1, +2, neg FISH) MBC
📍Ph III comparing T-Dxd vs 👨🏾⚕️ choice chemo
💉1-2 lines of prior chemo
📈Vast improvement in PFS and OS in HER2-low pop
📚#ShanuModi nejm.org
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @MammaMiaMagazin @AmericanCancer 9/17 #TumorBoardTuesday #BCSM #BreastCancer
👩🏽🏫Mini tweetorial 6👩🏻🏫
✨DAISY✨
📌T-DXd in HER2-zero MBC
📍Ph II single-arm
🔹T-Dxd for MBC for all levels of HER2 expression
💉>1 line of prior chemo
📈n=37 pts with HER2 zero MBC ➡️ ORR 29.7%
@MeganTesch
👩🏽🏫Mini tweetorial 6👩🏻🏫
✨DAISY✨
📌T-DXd in HER2-zero MBC
📍Ph II single-arm
🔹T-Dxd for MBC for all levels of HER2 expression
💉>1 line of prior chemo
📈n=37 pts with HER2 zero MBC ➡️ ORR 29.7%
@MeganTesch
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @MammaMiaMagazin 10/17 #TumorBoardTuesday #BCSM #BreastCancer
👩🏽🏫Mini tweetorial 7👩🏻🏫
✨DAISY✨
📌T-DXd in HER2-zero MBC
🔊Takeaway
📈Better PFS with greater HER2 expression
👉🏽Still possible at any HER2
📚@FerMosele @FAndreMD pubmed.ncbi.nlm.nih.gov
👩🏽🏫Mini tweetorial 7👩🏻🏫
✨DAISY✨
📌T-DXd in HER2-zero MBC
🔊Takeaway
📈Better PFS with greater HER2 expression
👉🏽Still possible at any HER2
📚@FerMosele @FAndreMD pubmed.ncbi.nlm.nih.gov
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @MammaMiaMagazin @FerMosele 11/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 8👩🏻🏫
🌴TROPICS-02🌴
📌Sacituzumab govitecan in ER+ MBC
📍Ph III comparing saci vs 👩🏿⚕️choice chemo
💉3-4 prior lines of systemic tx (including at least 1 taxane)
📈PFS 5.5m vs 4.0m / OS 14.4m vs 11.2m in favor of SG
👩🏽🏫Mini tweetorial 8👩🏻🏫
🌴TROPICS-02🌴
📌Sacituzumab govitecan in ER+ MBC
📍Ph III comparing saci vs 👩🏿⚕️choice chemo
💉3-4 prior lines of systemic tx (including at least 1 taxane)
📈PFS 5.5m vs 4.0m / OS 14.4m vs 11.2m in favor of SG
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly 12/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 9👩🏻🏫
🌴TROPICS-02 vs ✨DESTINY Breast-04
📌Sacituzumab govitecan in ER+ MBC
💉Patients pretreated more in 🌴TROPICS-02
📚@hoperugo @stolaney1 @JavierCortesMD pubmed.ncbi.nlm.nih.gov
📚pubmed.ncbi.nlm.nih.gov
👩🏽🏫Mini tweetorial 9👩🏻🏫
🌴TROPICS-02 vs ✨DESTINY Breast-04
📌Sacituzumab govitecan in ER+ MBC
💉Patients pretreated more in 🌴TROPICS-02
📚@hoperugo @stolaney1 @JavierCortesMD pubmed.ncbi.nlm.nih.gov
📚pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov/36027558/
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer - PubMed
SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety pr...
pubmed.ncbi.nlm.nih.gov/37633306/
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - PubMed
Gilead Sciences.
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo @stolaney1 @JavierCortesMD 13/17 #TumorBoardTuesday
Back to our case🔎
👩🏽 prefers pill 💊 based option
➡️ starts capecitabine
🗓️After 9 months
🩻experiences subsequent progression
🔀Switch to T-Dxd
🗓️Response for 12 months
🩻Progression in liver and 🦴
🧐What treatment would you offer next?
Back to our case🔎
👩🏽 prefers pill 💊 based option
➡️ starts capecitabine
🗓️After 9 months
🩻experiences subsequent progression
🔀Switch to T-Dxd
🗓️Response for 12 months
🩻Progression in liver and 🦴
🧐What treatment would you offer next?
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo @stolaney1 14/17 #TumorBoardTuesday
👩🏽🏫Mini tweetorial 10👩🏻🏫
🔁ADC after ADC (A3) 🔁
🔙Retro analysis
📍35 pts w/ MBC who received >1 ADC
🔊Takeaway: mPFS on ADC #1 > ADC #2
BUT
🤔Some STILL had durable response on ADC #2
‼️Need more data on this
📚@RachelAbelman ascopubs.org
👩🏽🏫Mini tweetorial 10👩🏻🏫
🔁ADC after ADC (A3) 🔁
🔙Retro analysis
📍35 pts w/ MBC who received >1 ADC
🔊Takeaway: mPFS on ADC #1 > ADC #2
BUT
🤔Some STILL had durable response on ADC #2
‼️Need more data on this
📚@RachelAbelman ascopubs.org
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo @stolaney1 15/17 #TumorBoardTuesday #BCSM #BreastCancer
🔥Just announced!🔥
✨TROPION-Breast01✨
📍Ph III comparing Dato-DXd to chemo
⬆️⬆️Dato-DXd significantly improves PFS vs chemo
🫁Low risk of ILD
🧑🏼🦲potentially less alopecia
🩸less neutropenia
📚@PTarantinoMD
🔥Just announced!🔥
✨TROPION-Breast01✨
📍Ph III comparing Dato-DXd to chemo
⬆️⬆️Dato-DXd significantly improves PFS vs chemo
🫁Low risk of ILD
🧑🏼🦲potentially less alopecia
🩸less neutropenia
📚@PTarantinoMD
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo 16/17 #TumorBoardTuesday
🌅On horizon🌅
💊More anti-estrogen options (SERM, SERD, PROTAC, CERAN, SERCA)
💉More ADC options
🔢Sequencing & personalizing tx approach for pts
‼️🧑🏽🔬Need more data/studies🔬‼️
📚@RimapatelMD @jsparano pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
🌅On horizon🌅
💊More anti-estrogen options (SERM, SERD, PROTAC, CERAN, SERCA)
💉More ADC options
🔢Sequencing & personalizing tx approach for pts
‼️🧑🏽🔬Need more data/studies🔬‼️
📚@RimapatelMD @jsparano pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov/37019913/
An emerging generation of endocrine therapies in breast cancer: a clinical perspective - PubMed
Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage hormone r...
pubmed.ncbi.nlm.nih.gov/35008318/
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs - PubMed
During recent years, a number of new compounds against HER2 have reached clinics, improving the prog...
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo @RimapatelMD @jsparano 17/17 #TumorBoardTuesday #BCSM #BreastCancer
Back to our case🔎
👩🏽 starts sacituzumab
On f/u has G1 fatigue 🥱 and neutropenia
🩸Monitor labs prior to each treatment (usually D1, D8 of 21d cycle)
🗓️ See in office q3wk
If AEs worsen, will assess need for dose reduction
Back to our case🔎
👩🏽 starts sacituzumab
On f/u has G1 fatigue 🥱 and neutropenia
🩸Monitor labs prior to each treatment (usually D1, D8 of 21d cycle)
🗓️ See in office q3wk
If AEs worsen, will assess need for dose reduction
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com
🤔@jane_meisel @quirogad taught us deciphering CDK4/6i in mBC, test yourself👇🏽
🤔What tx?
56yo 👩🏾🦱
HR+, HER2– (IHC 1+/FISH–)
endo-refractory mBC
pre-treated: AI + CDK4/6i, elac, & cape
🩻DP: 4L T-DXd
👉🏽#CME Eval 🔗 integrityce.com
🤔@jane_meisel @quirogad taught us deciphering CDK4/6i in mBC, test yourself👇🏽
🤔What tx?
56yo 👩🏾🦱
HR+, HER2– (IHC 1+/FISH–)
endo-refractory mBC
pre-treated: AI + CDK4/6i, elac, & cape
🩻DP: 4L T-DXd
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @marisirico @DSoldatoMD @Erman_Akkus @FAndreMD @dradityabardia @MeganTesch @JAMouabbi @DrGattiMays @drsarahsam @JasmineSukumar @StoverLab @parikhm @hdagli @RobertoBoreaMD @FlaviaJacobs_ @z_veitch @PiotrOkupski @Dr_RShatsky @ESchattner @RMJesel @DrWGradishar @Lucarecco @JHXII_13 @nardin_simone @IlanaSchlam @elmayermd @puglisi_fabio @BianchiniGP @prarthnavb @RenoHemonc @jesusanampa @nerealiamd @DenizCanGuven1 @amybeumer @tmprowell @aftimosp @pb61 @jackel626 @4RiseUp @awolff @brunovalsi @fumikochino @stage4kelly @hoperugo #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com
🧐Which investigational #BreastCancer therapy demonstrated PFS benefit:
📍Patients with HR+, HER2-low or HER2– mBC
✅Statistically significant
✅Clinically meaningful
👉🏽 Free CME 🔗 integrityce.com
🧐Which investigational #BreastCancer therapy demonstrated PFS benefit:
📍Patients with HR+, HER2-low or HER2– mBC
✅Statistically significant
✅Clinically meaningful
Loading suggestions...